January 26, 2009 — Top-line phase 3 results with oral cladribine in relapse-remitting multiple sclerosis (MS) show that the trial met its primary end point, with a 58% reduction in annualized relapse ...
The retrospective study was done in MS patients, the majority of whom had relapsing-remitting disease, and who took vitamin D2 (600-50,000 IU daily) or vitamin D3 (1,000-50,000 IU daily). A ...
Investment funds managed by Morgan Stanley Capital Partners (MSCP) today announced they completed the sale of Clarity Software Solutions (Clarity or the Company), a leading provider of health plan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback